The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
4D MOLECULAR THERAPEUTICS IN | COM | 35104E100 | 6,014 | 861,607 | SH | SOLE | 861,607 | 0 | 0 | ||
AMRYT PHARMA PLC | SPONSORED ADS | 03217L106 | 13,048 | 1,866,652 | SH | SOLE | 1,866,652 | 0 | 0 | ||
ARGENX SE | SPONSORED ADR | 04016X101 | 9,093 | 24,000 | SH | SOLE | 24,000 | 0 | 0 | ||
ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 42,200 | 1,198,515 | SH | SOLE | 1,198,515 | 0 | 0 | ||
ARVINAS INC | COM | 04335A105 | 32,483 | 771,745 | SH | SOLE | 771,745 | 0 | 0 | ||
BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 36,192 | 716,539 | SH | SOLE | 716,539 | 0 | 0 | ||
GENMAB A/S | SPONSORED ADS | 372303206 | 6,980 | 214,848 | SH | SOLE | 214,848 | 0 | 0 | ||
MERUS N V | COM | N5749R100 | 33,442 | 1,477,109 | SH | SOLE | 1,477,109 | 0 | 0 | ||
PIERIS PHARMACEUTICALS INC | COM | 720795103 | 6,987 | 3,736,280 | SH | SOLE | 3,736,280 | 0 | 0 | ||
REGENXBIO INC | COM | 75901B107 | 28,842 | 1,167,684 | SH | SOLE | 1,167,684 | 0 | 0 | ||
SPDR S&P BIOTECH ETF TR | UNIT | 78464A870 | 55,703 | 750,000 | SH | Put | SOLE | 0 | 0 | 750,000 | |
SPERO THERAPEUTICS INC | COM | 84833T103 | 3,943 | 5,321,231 | SH | SOLE | 5,321,231 | 0 | 0 | ||
UNIQURE NV | SHS | N90064101 | 18,109 | 971,490 | SH | SOLE | 971,490 | 0 | 0 |